Provided below are an analyst's forecasts of revenue, net operating profit after tax (NOPAT), and net operatir assets (NOA) as of 12/31/2019 for Abbott Laboratories. The following additional information is provided (dollar and share amounts in millions). - Common shares outstanding: 1,762.503 - Net nonoperating obligations (NNO): \$14,634.0 - Noncontrolling interest (NCI): \$213.0 - Preferred stock: $0.0 - WACC: 4.5% - Terminal growth: 2.0% Use the discounted cash flow (DCF) method to answer the following questions. Do not round intermediate calculations. All values other than per-share amounts are shown in millions. \begin{tabular}{|l|l|} \hline According to the DCF model, \\ what is the total value of the & [Select ] \\ firm? & \\ \hline According to the DCF model, what is the value per share of common stock? & [Select ] \\ \hline The company's stock closed at $87.45 on 02/21/2020, the date the 10K was filed with the SEC. In comparing your valuation estimate (also known as 'intrinsic value') & [Select ] \\ with the actual stock price, \\ was the stock overvalued or \\ undervalued, and why? & \\ \hline \end{tabular}